Opening Remarks: Dyslipidemia in Women

I feel honored to contribute to this special issue on lipid disorders in women in the form of a preface to IJCDW.ere indeed is a great need to research the available data from various sources and come out with guidelines to be followed for the benefit of Indian women with dyslipidemia.e format is well laid out, and all the contributing authors have done a great job.Dr. Hemanth Satpathy has given a panoramic view of dyslipidemia in pregnancy and how to rectify it. [1] Dr. Dayasagar Rao et al. [2] have well discussed the need to have targeted guidelines for Indian women.Dr. Lalita et al. [3] have given a nice contribution to understanding the genetic and ethnic determination of dyslipidemia in women and also discussed the paucity of data pertaining to women in various clinical trials.Dr. Harish et al. [4] have discussed the implications of LP(a), remnant cholesterol, and nonhigh-density lipoproteins (HDL) cholesterol in women.is is a lesser-known domain in lipid understanding in all and specifically in women.Dr. Priya et al. [5] have gone into the futuristic novel agents and their safety, efficacy aspects.is will add to our current pharmacotherapeutic strategies.Dr. Rammohan et al. [6] have elucidated on statin therapy in Indian women with dyslipidemia and the role of nonpharmacological strategies.Dr. Ramya et al. [7] have discussed the role of inclisiran and Small interfering -Ribonucleic acid (siRNA)-based lipid-lowering agents.is new frontier will be a very exciting prospect in the near future.Dr. Ritu Bhatia has delved into new HDL-targeted therapies.As we know, we have very few current options to deal with HDL. [8] Dr. Saeko et al. [9] have given us gender-specific guidelines insight for our clinical practice.Dr. Anuradha et al. [10] have us peep into the diagnosis of subclinical atherosclerosis in women which is of great significance in the prevention of atherosclerotic cardiovascular disease in women.Dr. Asha Mahilmaran et al. [11] have discussed dyslipidemia across the biological and physiological life span of women and gender differences along with hormonal impact.

Institutions

Publication Details

Journal
Indian Journal of Cardiovascular Disease in Women
Published
2025-12-12
DOI
https://doi.org/10.25259/ijcdw_85_2025
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Opening Remarks: Dyslipidemia in Women

Indian Journal of Cardiovascular Disease in Women
Lipoproteins and Cardiovascular Health
article

Opening Remarks: Dyslipidemia in Women

article en

Abstract

I feel honored to contribute to this special issue on lipid disorders in women in the form of a preface to IJCDW.ere indeed is a great need to research the available data from various sources and come out with guidelines to be followed for the benefit of Indian women with dyslipidemia.e format is well laid out, and all the contributing authors have done a great job.Dr. Hemanth Satpathy has given a panoramic view of dyslipidemia in pregnancy and how to rectify it. [1] Dr. Dayasagar Rao et al. [2] have well discussed the need to have targeted guidelines for Indian women.Dr. Lalita et al. [3] have given a nice contribution to understanding the genetic and ethnic determination of dyslipidemia in women and also discussed the paucity of data pertaining to women in various clinical trials.Dr. Harish et al. [4] have discussed the implications of LP(a), remnant cholesterol, and nonhigh-density lipoproteins (HDL) cholesterol in women.is is a lesser-known domain in lipid understanding in all and specifically in women.Dr. Priya et al. [5] have gone into the futuristic novel agents and their safety, efficacy aspects.is will add to our current pharmacotherapeutic strategies.Dr. Rammohan et al. [6] have elucidated on statin therapy in Indian women with dyslipidemia and the role of nonpharmacological strategies.Dr. Ramya et al. [7] have discussed the role of inclisiran and Small interfering -Ribonucleic acid (siRNA)-based lipid-lowering agents.is new frontier will be a very exciting prospect in the near future.Dr. Ritu Bhatia has delved into new HDL-targeted therapies.As we know, we have very few current options to deal with HDL. [8] Dr. Saeko et al. [9] have given us gender-specific guidelines insight for our clinical practice.Dr. Anuradha et al. [10] have us peep into the diagnosis of subclinical atherosclerosis in women which is of great significance in the prevention of atherosclerotic cardiovascular disease in women.Dr. Asha Mahilmaran et al. [11] have discussed dyslipidemia across the biological and physiological life span of women and gender differences along with hormonal impact.

Indian Journal of Cardiovascular Disease in WomenVol. 10
CARE Hospitals (IN)
Gender equality
Openalex Percentile: Top 28%
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Opening Remarks: Dyslipidemia in Women · Indian Journal of Cardiovascular Disease in Women (2025) | TGRS Research Map | TGRS